Compare VUZI & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VUZI | ARCT |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.1M | 194.1M |
| IPO Year | N/A | N/A |
| Metric | VUZI | ARCT |
|---|---|---|
| Price | $2.76 | $7.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.67 |
| AVG Volume (30 Days) | ★ 1.6M | 892.4K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,310,001.00 | ★ $97,601,000.00 |
| Revenue This Year | $5.53 | N/A |
| Revenue Next Year | $110.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.47 | $5.85 |
| 52 Week High | $5.79 | $24.17 |
| Indicator | VUZI | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 41.80 |
| Support Level | $2.42 | $7.04 |
| Resistance Level | $3.20 | $7.76 |
| Average True Range (ATR) | 0.19 | 0.40 |
| MACD | 0.06 | 0.42 |
| Stochastic Oscillator | 55.50 | 75.21 |
Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.